Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06418880 · ClinicalTrials.gov registry record · Phase 3

Automated Insulin Delivery for Inpatients With Dysglycemia

A Phase 3 study of Type 2 Diabetes and Type 1 Diabetes, sponsored by Emory University.

Completed
Registry status
Phase 3
Development phase
130
Enrollment target
3
Study locations

NCT06418880 is a Phase 3 study of Type 2 Diabetes and Type 1 Diabetes that has completed, run by Emory University. The registered enrollment target is 130 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06418880, a Phase 3 study of Type 2 Diabetes and Type 1 Diabetes, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 3
Development phase
130 participants
Enrollment target
3
Study locations

Study Summary

This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the efficacy and safety of AID versus multiple daily insulin injections (MDI) + CGM in the inpatient setting * To determine differences in CGM-derived metrics between AID and MDI plus CGM in the hospital and explore differences in treatment effect according to individual characteristics. Participants will be: * Randomized to AID + remote CGM (intervention) or multiple daily insulin injections (MDI) + CGM (control group) * Followed for a total of 10 days or until hospital discharge (if less than 10 days).

Conditions Studied

Type 2 Diabetes Type 1 Diabetes

Interventions

  • DEVICE AID system with Remote Real-Time CGM
  • COMBINATION_PRODUCT Standard of Care Insulin Therapy + CGM

Study Locations (3)

California

  • Stanford University School of Medicine - Stanford

Georgia

  • Grady Health System (non-CRN) - Atlanta

Virginia

  • University of Virginia School of Medicine - Charlottesville

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-01-22
Est. Completion 2025-10-31
Phase Phase 3

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06418880

The ClinicalTrials.gov registry entry for NCT06418880 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which AID system with Remote Real-Time CGM is the first listed.

NCT06418880 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Virginia.

Frequently Asked Questions

What is clinical trial NCT06418880 about?

NCT06418880 is a clinical study titled "Automated Insulin Delivery for Inpatients With Dysglycemia". This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admitted to general medical/surgical floors. The main objectives of this study are: * To test the effic...

What is the current status of trial NCT06418880?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2025-01-22. Estimated completion is 2025-10-31.

What conditions does trial NCT06418880 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Type 1 Diabetes.

What interventions are being tested in trial NCT06418880?

The interventions under investigation include: AID system with Remote Real-Time CGM (DEVICE), Standard of Care Insulin Therapy + CGM (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06418880?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06418880 being conducted?

This trial has 3 study locations across California, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Type 1 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.